Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 study

Natasha B. Leighl, Matthew David Hellmann, Rina Hui et al. · The Lancet Respiratory Medicine · 2019

Cited by 174 works. doi:10.1016/s2213-2600(18)30500-9

Authors

References